Transcode Therapeutics, Inc. 8-K

What Happened

• On January 6, 2026, TransCode Therapeutics, Inc. (NASDAQ: RNAZ) issued a press release announcing the publication of preclinical research on its lead candidate, TTX‑MC138, for the treatment of glioblastoma multiforme. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8‑K under Item 7.01 (Regulation FD Disclosure).

Key Details

• Press release date: January 6, 2026; furnished as Exhibit 99.1 to the Form 8‑K.
• Topic: publication of preclinical research data for TTX‑MC138 targeting glioblastoma multiforme.
• Filing: Current Report on Form 8‑K (Regulation FD Disclosure) — no financial results or clinical trial starts were reported in this filing.

Why It Matters

• Publication of preclinical data is a milestone in TransCode’s R&D progress and can inform investor assessment of the company’s pipeline advancement and scientific validation for TTX‑MC138.
• This 8‑K is a disclosure of newly public scientific information rather than financial performance; investors should read the press release (Exhibit 99.1) for details and monitor future filings or announcements for clinical development or commercial implications.